Home
Issues
2022
April 2022 Vol 12, No 2
March 2022 Vol 12 Special Feature
February 2022 Vol 12, No 1
2021
December 2021 Vol 11, No 6
October 2021 Vol 11, No 5
August 2021 Vol 11, No 4
June 2021 Vol 11, No 3
April 2021 Vol 11, No 2
March 2021 Vol 11 Special Feature
February 2021 Vol 11, No 1
2020
December 2020, Vol 10, No 6
October 2020, Vol 10, No 5
August 2020, Vol 10, No 4
June 2020, Vol 10, No 3
April 2020 Vol 10, No 2
February 2020 Vol 10, No 1
Issue Archive
Online First
Special Issues
Supplements
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Renal-Cell Carcinoma
Breast Cancer
Ovarian Cancer
Biosimilars
Non–Small-Cell Lung Cancer
Gastrointestinal Cancer
Categories
Conference Correspondent
Dual IO 2021 Year in Review
AACR & ASCO 2021 - Midyear Review
ASCO 2021 Breast Cancer Highlights
ASCO Highlights
ASH Highlights
ESMO Highlights
SABCS Highlights
Web Exclusives
All Web Exclusives
Interview with the Innovators
FDA Approvals
Videos
Press Releases
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Melanoma Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise
Subscribe
Sign Up Now!
To sign up for our newsletter or print publications, please enter your contact information below.
First Name
*
Last Name
*
Email Address
*
Email Address (Verify)
*
JHOP Print Edition
We will request your mailing address on the next page.
JHOP E-Newsletters & Communications
TOP Print Edition
We will request your mailing address on the next page.
TOP E-Newsletters & Communications
I have reviewed and consent to the terms of
JHOP
's
Privacy Policy
, and
JHOP
has my permission to retain my information in its database, and to forward pertinent communications to me.
Home
Issues
2022
April 2022 Vol 12, No 2
March 2022 Vol 12 Special Feature
February 2022 Vol 12, No 1
2021
December 2021 Vol 11, No 6
October 2021 Vol 11, No 5
August 2021 Vol 11, No 4
June 2021 Vol 11, No 3
April 2021 Vol 11, No 2
March 2021 Vol 11 Special Feature
February 2021 Vol 11, No 1
2020
December 2020, Vol 10, No 6
October 2020, Vol 10, No 5
August 2020, Vol 10, No 4
June 2020, Vol 10, No 3
April 2020 Vol 10, No 2
February 2020 Vol 10, No 1
Issue Archive
Online First
Special Issues
Supplements
Guide to New FDA Approvals
2021 Year in Review
Multiple Myeloma
Advances in Dual Immunotherapy Cancer Treatments
Renal-Cell Carcinoma
Breast Cancer
Ovarian Cancer
Biosimilars
Non–Small-Cell Lung Cancer
Gastrointestinal Cancer
Categories
Conference Correspondent
Dual IO 2021 Year in Review
AACR & ASCO 2021 - Midyear Review
ASCO 2021 Breast Cancer Highlights
ASCO Highlights
ASH Highlights
ESMO Highlights
SABCS Highlights
Web Exclusives
All Web Exclusives
Interview with the Innovators
FDA Approvals
Videos
Press Releases
Lung Cancer Monthly Minutes
Gastrointestinal Cancer Monthly Minutes
Melanoma Monthly Minutes
For Authors
Author Guidelines
Symptom Management Overview
Letters to the Editor Instructions
Peer Review Application
Submit a Manuscript
About
About JHOP
Contact Us
Editorial Policies
Peer-Review Process
About the Editors
Editorial Board
Editorial Process
Advertising Contacts
Advertising Policy
Advertise
JHOP - October 2021 Vol 11, No 5
Editorial
Case Reports
Original Article
Review Article
FDA Oncology Update
Editorial
Urine Alkalinization and Methotrexate Clearance: Are These Key to Safe Administration of High-Dose Methotrexate?
Joseph Bubalo, PharmD, BCPS, BCOP
Read More
Case Reports
Successful Treatment of Nivolumab plus Ipilimumab–Mediated Pure Red-Cell Aplasia and Diabetes with Cyclosporine
Parikshit Padhi, MD, MBBS; Traci M. White, PharmD, PhC, BCGP; Neslihan Cetin, MD
Read More
Original Article
Outcomes of Pharmacist-Provided Telehealth Services in an Ambulatory Oncology Clinic During the COVID-19 Pandemic
Colleen Bohnenkamp, PharmD, BCOP, BCPS; Grace A. Martin, PharmD, BCOP; Laure Dubois, PharmD, BCOP; Olivia Fahey, PharmD, BCOP; Jade Hefler, PharmD
Read More
Tolerance of Oral Targeted Therapies in Patients with Metastatic Renal-Cell Carcinoma and Renal Impairment
Jessica McKernan, PharmD, BCOP; Laura Schmidt, PharmD, BCOP; Melissa Rhoades, PharmD, BCOP
Read More
Efficacy of an Enteral Urine Alkalinization Strategy During Intravenous Sodium Bicarbonate Shortage in Patients with Cancer Receiving High-Dose Methotrexate
Christopher Sinoimeri, PharmD; Matthew Lei, PharmD, BCOP; Stephanie Monaco, PharmD, BCOP; Uvette Lou, PharmD, BCOP
Read More
Review Article
Recent Targeted Therapies Approved for the Treatment of Patients with Urothelial Carcinoma
Bojana Stevich-Heemer, MS, PharmD, MEd, BCOP
Read More
FDA Oncology Update
Online First
Tivdak First Antibody–Drug Conjugate FDA Approved for Recurrent or Metastatic Cervical Cancer
Read More
Online First
Exkivity Novel Oral Targeted Therapy Approved for Metastatic NSCLC with EGFR Exon 20 Insertion Mutations
Read More
Online First
Welireg FDA Approved for 3 Tumor Types Associated with von Hippel-Lindau Disease
Read More
Online First
Rezurock Novel Oral Therapy FDA Approved for Chronic Graft-Versus-Host Disease
Read More
Online First
Jakafi a New Treatment Option for Chronic Graft-Versus-Host Disease
Read More
Online First
Cabometyx Receives FDA Approval for Differentiated Thyroid Cancer
Read More
Brukinsa Approved for Marginal-Zone Lymphoma and for Waldenström’s Macroglobulinemia
Read More
Online First
Jemperli Another Therapy Approved for Patients with dMMR Recurrent or Advanced Solid Tumors
Read More
Online First
Lenvima plus Keytruda a New Combination Approved for Advanced Renal-Cell Carcinoma
Read More
Privacy policy
Terms of Use
Home
About
Subscribe
Advertise
Contact Us
Copyright © Green Hill Healthcare Communications, LLC. All rights reserved.
